Trial reportFrontiers in immunology2020
Adjunct N-Acetylcysteine Treatment in Hospitalized Patients With HIV-Associated Tuberculosis Dampens the Oxidative Stress in Peripheral Blood: Results From the RIPENACTB Study Trial.
Trial report in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Vascular endothelial growth factor levels in tuberculosis: A systematic review and meta-analysis.PloS one · 2022Pooled it
- Response to Intravenous N-Acetylcysteine Supplementation in Critically Ill Patients with COVID-19.Nutrients · 2023Trial
- Efficacy and Safety of Glutathione Supplementation in Patients with HIV Infection and HIV-Tuberculosis Co-Infection.Nutrients · 2026Review
- Glutathione-Mediated Redox Regulation of Immune Dysfunction in COVID-19 and Tuberculosis.Antioxidants (Basel, Switzerland) · 2026Review
- Knowledge, attitude and practice in tuberculosis treatment among HIV-positive patients: Association with sputum conversion-A mixed-methods study.Bioinformation · 2026Article
- Current and emerging therapies for pulmonary tuberculosis in adults.BMJ medicine · 2026Review
- N-acetylcysteine: evidence based consensus document on the therapeutic advantages in respiratory diseases (NECTAR).Frontiers in medicine · 2026Review
- Combating biofilm formation and bacterial killing: N-acetylcysteine's efficacy againstBiofilm · 2025Article
- Review
- Oxidative Stress in People Living With HIV: Are Diverse Supplement Sources the Solution?Health science reports · 2025Review
- N-Acetylcysteine as a Host-Directed Therapy Against Clarithromycin-ResistantPathogens (Basel, Switzerland) · 2025Article
- Repurposed Drugs and Plant-Derived Natural Products as Potential Host-Directed Therapeutic Candidates for Tuberculosis.Biomolecules · 2024Review
- Promoting Glutathione Synthesis: A Possibility for Treating Cardiomyopathy Induced by a Maternal Western Diet.Nutrients · 2024Article
- Immunopathology of PulmonaryInternational journal of molecular sciences · 2024Article
- Effects of Acetyl-L-Carnitine on Oxidative Stress in Amyotrophic Lateral Sclerosis Patients: Evaluation on Plasma Markers and Members of the Neurovascular Unit.Antioxidants (Basel, Switzerland) · 2023Article
- Changes in the balance of Th17/Treg cells and oxidative stress markers in patients with HIV‑associated pulmonary tuberculosis who develop IRIS.Experimental and therapeutic medicine · 2023Article
- Glutathione Modulates Efficacious Changes in the Immune Response against Tuberculosis.Biomedicines · 2023Review
- Antiviral and ROS scavenging potential of Carica papaya Linn and Psidium guajava leaves extract against HIV-1 infection.BMC complementary medicine and therapies · 2023Article
- Impact ofAntioxidants (Basel, Switzerland) · 2022Review
- GPX4 regulates cellular necrosis and host resistance in Mycobacterium tuberculosis infection.The Journal of experimental medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
Abstract
Tuberculosis (TB) still causes significant morbidity and mortality worldwide, especially in persons living with human immunodeficiency virus (HIV). This disease is hallmarked by persistent oxidative stress and systemic inflammation. N-acetylcysteine (NAC), a glutathione (GSH) precursor, has been shown in experimental models to limit
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.